Spruce Biosciences Advances TA-ERT Program Following Constructive Type B Discussions with U.S. FDA
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. a late-stage biopharmaceutical company focused on…
KalVista’s EKTERLY® Added as First-Line Treatment for Patients Aged 12+ in Pediatric HAE Guideline
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline KalVista Pharmaceuticals, Inc. today announced that the newly published…
Korsana Biosciences Launches with $175 Million to Develop Innovative Neurodegenerative Treatments
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases Korsana Biosciences, Inc. a biotechnology company discovering and developing novel therapies to…
GenSight Biologics Expands Regulatory Team Across the U.S. and Europe
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments GenSight Biologics a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases…
New Study Highlights Flashpoint Therapeutics’ Breakthrough HPV Cancer Vaccine
Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the…
Janux Therapeutics Doses First Patient in Phase 1 Trial of JANX011
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the…
Twist Bioscience Broadens Antibody Discovery Portfolio Through New Bispecific Licensing Deal
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement Twist Bioscience Corporation a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement…
Deciphera’s Tirabrutinib NDA Accepted by FDA for Relapsed or Refractory PCNSL
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL Deciphera Pharmaceuticals, a member of Ono…
NationsBenefits and Kinney Drugs Expand Flex Card Access in New York
NationsBenefits and Kinney Drugs Partner to Expand Flex Card Access for Rx and OTC Health Needs in New York NationsBenefits, the leading healthcare fintech and supplemental benefits platform, announced a…
FDA Accepts Bristol Myers Squibb’s NDA for Iberdomide in Relapsed or Refractory Multiple Myeloma
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb today announced that the U.S.…
BRAFTOVI Regimen from Pfizer Demonstrates Improved PFS in Advanced Colorectal Cancer
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer Pfizer Inc. today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal…
ImmunityBio Advances Regulatory Collaboration at USA-Saudi Biotech Alliance Event in Saudi Arabia
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia ImmunityBio, Inc. a commercial stage…